Business
60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study
Breakthrough Therapy Designation request has been submitted to FDACompany to request a Type B meeting with FDA in early 2026 to discuss requirements for a supplementary New Drug Application (sNDA)Results obtained using highest sensitivity test available; licensed by FDA for blood donation screeningRemaining enrolled patients will complete the study between January and October 2026Study intended to confirm the high cure rate for tafenoquine in immunosuppressed patients with relapsing babesiosis,
About this update from 60 Degrees Pharmaceuticals, Inc.
[{"type":"image","alt":"Sixty Degrees Pharmaceuticals","displaySize":"","headline":null,"caption":"Sixty Degrees Pharmaceuticals","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/6c5f734cbdeffb0ff816df4f768b5fa6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/L1lrb.zKykt_bMbAkYncaQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6c5f734cbdeffb0ff816df4f768b5fa6","width":300,"height":157}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Breakthrough Therapy Designation request has been submitted to FDA","length":66,"tagName":"p"}]},{"val":[{"type":"text","content":"Company to request a Type B meeting with FDA in early 2026 to discuss requirements for a supplementary New Drug Application (sNDA)","length":130,"tagName":"p"}]},{"val":[{"type":"text","content":"Results obtained using highest sensitivity test available; licensed by FDA for blood donation screening","length":103,"tagName":"p"}]},{"val":[{"type":"text","content":"Remaining enrolled patients will complete the study between January and October 2026","length":84,"tagName":"p"}]},{"val":[{"type":"text","content":"Study intended to confirm the high cure rate for tafenoquine in immunosuppressed patients with relapsing babesiosis, as reported by Yale in a 2024 publication","length":158,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":541,"olType":false},{"type":"text","content":"WASHINGTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that the first patient to have completed the regimen in the Company’s trial of relapsing babesiosis in immunosuppressed patients has tested negative for babesiosis. The trial is an expanded access study of ARAKODA® (tafenoquine) in combination with conventional treatments for relapsing babesiosis (NCT06478641).","length":554,"tagName":"p"},{"type":"text","content":"Babesiosis is a tick-borne illness caused by Babesia parasites that develop and multiply in red blood cells. Symptoms include fevers, chills, sweats, and fatigue. In severe cases, babesiosis can be life-threatening in elderly and immunosuppressed patie...